MedPharm licenses its MedSpray patch-in-a-can technology

The topical and transdermal specialist has licensed its technology to Virpax Pharmaceuticals, a pain management company

MedPharm, specialists in topical and transdermal development, has licensed its MedSpray technology to Virpax Pharmaceuticals, a company based in Pennsylvania, US that specialises in developing pharmaceutical products for pain management by using new drug delivery systems.

MedSpray is covered by worldwide patents and delivers transdermal patch technology in a metered-dose aerosol spray. The thin film patch created on the skin or mucosal membrane has been demostrated in clinical trials to provide long-lasting efficacy for patients.

MedPharm is now well-established as the leader in dermatological, nail, eye, airway, mucosal membrane and transdermal product development. In the last 20 years, MedPharm has built a worldwide reputation for helping clients navigate the complex route to successful development of its pharmaceutical products.

In parallel with fees for service work, MedPharm is constantly looking for opportunities to develop new formulation and drug delivery technologies such as MedSpray, which enhances clients’ products, provides clinical benefits for patients and meets the increasingly stringent requirements of regulatory authorities.

MedPharm is working closely with Virpax to develop DSF100, an investigational spray film designed to deliver an NSAID transdermally via a metered-dose spray. The delivery system features a high level of adhesiveness, accessibility and skin drying. Virpax filed a pre-IND meeting request with the US Food and Drug Administration (FDA) and it was granted on 18 May, 2018.

“MedSpray’s unique dosing offers clients the opportunity to differentiate their product and potentially achieve premium pricing for extended effects,” said Dr Jeremy Drummond, MedPharm’s SVP of Business Development.

“We are looking forward to partnering with Virpax to bring products with our MedSpray technology to market.”

“We believe there is an opportunity to explore the development of non-opioid transdermal pain treatments that improve on existing gel and patch products, for which adhesion and accessibility can be a challenge,” said Anthony Mack, CEO of Virpax.

“We believe that the ‘Patch-in-a-Can’ technology offers a promising delivery system and we are excited to be collaborating with a world leader like MedPharm,” Mack said.

Companies